Pasireotide cas 396091-73-9

Pasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Related Prodcuts:

Icatibant; Lanreotide; Nesiritide; Leuprolide Acetate; Liraglutide; Lypressin; Atosiban; Oxytocin; Bivalirudin; Pramlintide Acetate; Calcitonin Salmon; Alarelin Acetate; Sincalide; Somatostatin Acetate; Glucagon HCl

1: Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. Pituitary. 2016 Oct;19(5):536-43. doi: 10.1007/s11102-016-0734-1. Review. PubMed PMID: 27405306.

2: Pasireotide (Signifor): Treatment of Adult Patients with Cushing Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK349174/ PubMed PMID: 26962592.